Bausch Health Companies stock surged nearly 40% in July 2026, driven by a regulatory win in Canada for its Prokedi schizophrenia drug and a strong Q2 earnings beat. The company reported $2.85 billion in revenue (13% YoY growth) and adjusted net income of $476 million ($1.26 per share), exceeding analyst expectations. Management raised full-year 2026 guidance for both revenue and adjusted EBITDA, citing strength across its diversified pharmaceutical portfolio.

The hepatic encephalopathy market is projected to grow at 1.2% CAGR through 2036, valued at USD 900 million in 2025. Growth is driven by rising prevalence of chronic liver diseases, improved early diagnosis awareness, and emerging therapies from companies like Vedanta Biosciences, Yaqrit Discovery Ltd, and others. The US dominates with 60% market share, with approximately 210,000 prevalent cases across the 7MM in 2025.

Bausch Health Companies reported Q1 2026 earnings that beat analyst expectations with $2.52 billion in revenue (up 12% YoY) and non-GAAP net income of $0.78 per share (up 35% YoY), exceeding consensus estimates of $2.42 billion and $0.68 per share respectively. The company maintained its full-year 2026 guidance and highlighted 12 consecutive quarters of revenue growth, driving the stock up nearly 2% for the week.

The pheochromocytoma and paraganglioma (PCPG) market is projected to grow at 7.3% CAGR through 2036, driven by emerging therapies including radioligand treatments, HIF-2α inhibitors, and targeted agents. The market was valued at USD 300 million in 2025 across seven major markets, with the US accounting for 67% of the market. Key companies including Novartis, Jazz Pharmaceuticals, Perspective Therapeutics, and Merck are advancing innovative treatments, with WELIREG (belzutifan) expected to generate the highest revenue by 2036.

The global dermatology devices market is projected to grow from $14.4 billion in 2024 to $25.6 billion by 2030, with a CAGR of 10.4%. Growth is driven by rising skin cancer incidence, aging populations, aesthetic procedure demand, and technological innovations including picosecond lasers and 3D bioprinting. North America leads with 52.3% market share.

The global scar treatment market is projected to grow from USD 26.60 billion in 2025 to USD 56.30 billion by 2033, with a CAGR of 9.91%. Growth is driven by increasing awareness of advanced cosmetic and reconstructive procedures, rising prevalence of acne, surgical, and traumatic scars, and technological advancements in minimally invasive treatments. The U.S. market alone is expected to reach USD 17.69 billion by 2033.

The Energy-Based Aesthetic Devices Market is projected to grow from USD 7.03 billion in 2025 to USD 11.80 billion by 2031 at a CAGR of 9.02%. Growth is driven by increased demand for hair removal treatments, med-spa expansion, minimally invasive procedures, and AI integration. Laser-based technology dominates the market, with North America leading globally. Key challenges include rising health and wellness awareness and high device costs.

The global ophthalmic drugs market is projected to grow from USD 37.35 billion in 2023 to USD 62.74 billion by 2032, driven by increasing eye disorders, advanced drug delivery methods, and rising healthcare awareness.

Bausch Health Companies' stock rose 11% after acquiring Wuhan Shibo Zhenmei Technology, a distributor of its aesthetic products in China, which enhances its market presence in the region.

Stock markets experienced a mixed day with major indexes declining, while individual stocks showed significant movements. Healthcare and technology stocks saw notable performance changes, with some companies experiencing substantial gains or losses.

The article highlights five stocks trading under $10 that show potential for significant price appreciation, driven by factors like user growth, economic recovery, and strategic improvements in their respective industries.

Questex's Fierce Pharma Marketing Awards celebrated innovative pharmaceutical marketing campaigns across 18 categories, highlighting creative approaches to addressing global health challenges.